Schrodinger SDGR Drug discovery contribution — Total revenues

Other product segments

Similar metrics at other companies

DNLITherapeutics Segment — Total collaboration revenue

$0—

TARSLicense fees and collaboration revenue — Total revenues

$16.67M—

CRNXCollaboration and license revenue — Total Revenue

$428K+18.6%

BCRXCollaborative and other revenues — Total revenues

$2M+14.3%

RCUSLicense and development services — Total revenues

$12M-40.0%

VCYTBiopharmaceutical revenue — Total Revenue

$301K-86.9%

Questions, answered.

What is Schrodinger's drug discovery contribution — total revenues?

Schrodinger (SDGR) reported drug discovery contribution — total revenues of $148K in Q1 2026.

How has Schrodinger's drug discovery contribution — total revenues changed year-over-year?

Schrodinger's drug discovery contribution — total revenues decreased by 70.3% year-over-year, from $499K to $148K.

What does drug discovery contribution — total revenues mean?

Represents the aggregate gross revenue generated by the drug discovery segment, including all collaborative research and preclinical program activities. This metric serves as a primary indicator of the segment's market traction and its ability to monetize internal research efforts. It provides investors with a clear view of the top-line performance specifically attributable to the company's drug discovery business model.